Immune responses to the oral administration of recombinant Bacillus subtilis expressing multi-epitopes of foot-and-mouth disease virus and a cholera toxin B subunit.
Bacillus subtilis has been engineered successfully to express heterologous antigens for use as a vaccine vehicle that can elicit mucosal and systemic immunity response. In this study, a recombinant B. subtilis expressing the B subunit of cholera toxin (CT-B) and an epitope box constituted with antigen sites from foot-and-mouth disease virus (FMDV) type Asia 1 was constructed and named 1A751/CTB-TEpiAs. Its capability to induce mucosal, humoral, and cellular responses in mice and guinea pigs was evaluated after oral administration with vegetative cells of 1A751/CTB-TEpiAs. In addition, its capability to protect guinea pigs against homologous virus challenge was examined. All animals were given booster vaccination at day 21 after initial inoculation and guinea pigs were challenged 3 weeks after booster vaccination. The control groups were inoculated with a commercial vaccine or administered orally with 1A751/pBC38C or an oral buffer. All animals vaccinated with 1A751/CTB-TEpiAs developed specific anti-FMDV IgA in lung and gut lavage fluid, serum ELISA antibody, neutralizing antibody as well as T lymphocyte proliferation, and IFN-γ secretory responses. Three of the five guinea pigs vaccinated with 1A751/CTB-TEpiAs were protected completely from the viral challenge. The results demonstrate the potential viability of a B. subtilis-based recombinant vaccine for the control and prevention of FMDV infections.
College of Animal Science and Veterinary Medicine, Jilin University, Changchun, China.
Bo
B
Hu
Chang
C
Li
Huijun
H
Lu
Zhanbo
Z
Zhu
Shouwen
S
Du
Ming
M
Ye
Lei
L
Tan
Dayong
D
Ren
Jiali
J
Han
Shifu
S
Kan
Jing
J
Wang
Ningyi
N
Jin
D000276:Adjuvants, Immunologic / Q000235:genetics / Q000378:metabolism*; D000284:Administration, Oral; D000818:Animals; D057134:Antibodies, Neutralizing / Q000032:analysis / Q000097:blood; D000914:Antibodies, Viral / Q000032:analysis / Q000097:blood; D001208:Asia; D001412:Bacillus subtilis / Q000235:genetics* / Q000254:growth & development / Q000276:immunology; D002772:Cholera Toxin / Q000235:genetics / Q000378:metabolism*; D004337:Drug Carriers; D000939:Epitopes / Q000235:genetics / Q000276:immunology; D005260:Female; D029544:Foot-and-Mouth Disease Virus / Q000235:genetics / Q000276:immunology*; D041981:Gastrointestinal Tract / Q000276:immunology; D005822:Genetic Vectors; D006168:Guinea Pigs; D018928:Immunity, Mucosal; D007117:Immunization, Secondary / Q000379:methods; D007070:Immunoglobulin A / Q000032:analysis; D007371:Interferon-gamma / Q000378:metabolism; D008168:Lung / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000276:immunology; D014611:Vaccination / Q000379:methods; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
D000276:Adjuvants, Immunologic; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D004337:Drug Carriers; D000939:Epitopes; D007070:Immunoglobulin A; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; D007371:Interferon-gamma; D002772:Cholera Toxin